Bioorganic & medicinal chemistry letters · 2018
Discovery of evocalcet, a next-generation calcium-sensing receptor agonist for the treatment of hyperparathyroidism.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Miyazaki Hiroshi, Ikeda Yousuke, Sakurai Osamu, Miyake Tsutomu, Tsubota Rie, Okabe Jyunko, Kuroda Masataka, Hisada Yutaka, Yanagida Tetsuya, Yoneda Hikaru, Tsukumo Yukihito, Tokunaga Shin, Kawata Takehisa, Ohashi Rikiya, Fukuda Hajime, Kojima Koki, Kannami Ayako, Kifuji Takayuki, Sato Naoya, Idei Akiko, Iguchi Taku, Sakairi Tetsuya, Moritani Yasunori
Аннотация
The calcium-sensing receptor (CaSR) plays an important role in sensing extracellular calcium ions and regulating parathyroid hormone secretion by parathyroid gland cells, and the receptor is a suitable target for the treatment of hyperparathyroidism. Cinacalcet hydrochloride is a representative CaSR agonist which widely used for the hyperparathyroidism. However, it has several issues to clinical use, such as nausea/vomiting and strong inhibition of CYP2D6. We tried to improve these issues of cinacalcet for a new pharmaceutical agent as a preferable CaSR agonist. Optimization from cinacalcet resulted in the identification of pyrrolidine compounds and successfully led to the discovery of evocalcet as an oral allosteric CaSR agonist. Evocalcet, which exhibited highly favorable profiles such as CaSR agonistic activity and good DMPK profiles, will provide a novel therapeutic option for secondary hyperparathyroidism.